Current Opportunities

---

We currently represent select medical technology companies at the critical inflection point. Each has completed comprehensive due diligence and meets our standards for late-stage development readiness.

Every company has:

· Proven technology with clinical or real-world validation

· Secured intellectual property and freedom to operate

· Strong management team with relevant experience

· Clear regulatory pathway to approval

· Exhausted early-stage funding sources

· Capital requirement of $10-50 million for commercialization

If you're an institutional investor or family office interested in pre-vetted healthcare opportunities at this specific stage, we'd welcome a confidential discussion.

We are currently evaluating several late-stage opportunities in:

· Neurological therapeutics

· Oncology diagnostics and treatment

· Regenerative medicine platforms

· Medical device technologies

· Rehabilitation and mobility solutions

Each opportunity has been rigorously vetted and is positioned for institutional capital deployment.

Contact us to discuss current opportunities that align with your investment criteria.